Johnson & Johnson Innovative Medicine

We’re restoring the true meaning of?healthcare—developing advanced treatments and smarter and less invasive solutions for today’s most complex diseases. See how?we're?connecting the best of Health&Care for?every patient and provider.?https://lnkd.in/eW-mXA49

For people with generalized myasthenia gravis (gMG), symptoms such as difficulty speaking and swallowing, limb weakness, and double vision are a daily reality. gMG can also significantly impact a person’s mental health. Johnson & Johnson’s goal is to offer solutions that improve the lives of people living with gMG and other autoantibody-driven diseases. With 25 accepted abstracts at the 2024 #AANEMinSavannah, we look forward to showcasing our latest research that we hope will one day impact the treatment landscape for autoantibody-driven neurological diseases. Learn more about what our latest research means for gMG patients and their healthcare providers: https://lnkd.in/eWcQFkGs

We recently joined more than 125 patient advocates and caregivers for our HealtheVoices 2024 Conference – an annual event designed for advocates, by advocates, to learn, connect, and inspire each other’s efforts. Attendees participated in sessions from creating accessible content and driving inclusive research to leveraging entertainment as a form of education, with special performances throughout the weekend from this talented community.? ? On the mainstage, Johnson & Johnson C.E.O. Joaquin Duato was joined by 2024 advisor and pulmonary arterial hypertension (PAH)?advocate, Sophia Esteves, for a conversation about the relationship between patient advocacy and healthcare.?? ? Another conference highlight was this year’s keynote speaker and disability, LGBTQIA+, and mental health activist, Carson Tueller, who shared his incredible story and reminded attendees that “we are, and always have been, whole and complete.”?? In its 10th year, HealtheVoices was filled with reflection and celebration—as patient advocates, representing a wide variety of conditions, came together to recognize a decade of impact, while looking forward to inspiring the future of healthcare.? ? We’re grateful for how they champion others. We’re moved by their stories. And we’re so honored to learn alongside this incredible community who inspire us to advance care and bridge inequities for patients everywhere.?? ? #HealtheVoices24 #PatientAdvocacy?

For more than two decades, we have been dedicated to developing novel and effective therapies, with a relentless focus on individuals living with chronic conditions such as Crohn’s disease (CD) and ulcerative colitis (UC) who experience persistent and debilitating symptoms. We are proud to present Phase 3 data from our studies evaluating the robust results of a novel treatment option for patients with moderately to severely active CD and UC, across all patient populations. We look forward to engaging in meaningful conversations about our latest data with experts at UEG - United European Gastroenterology Week. Learn more about these findings: https://lnkd.in/eB5zq_ZN #UEGW2024 #JNJImmunology

Being diagnosed with a rare or life-threatening disease can be devastating, leaving patients and their loved ones urgently seeking answers and treatment options. But what if the next innovative treatment was around the corner – and what if that treatment was available now? Imagine the relief and joy of knowing that a breakthrough treatment could provide more precious moments. At Johnson & Johnson Innovative Medicine, we believe that patients should be given every chance to access faster-approved treatments – which the U.S. FDA’s Accelerated Approval Program can help provide. In the below article, Ginny Beakes-Read, Head of Global Regulatory Policy and Intelligence, details the benefits of the program and the first-of-its-kind study that quantified the program’s positive impact for cancer patients. Read it here: https://lnkd.in/ehCFsEqR

Our deep understanding of the coagulation cascade is guiding our exploration of Factor XIa inhibition in collaboration with Bristol Myers Squibb. Together, our goal is to help minimize bleeding and lower the risk of stroke for patients living with thrombotic conditions. #WTDay24

We’re excited to share You, Me and MG with the world. This brand-new online community will tell the stories of people living with #MyastheniaGravis (MG) and raises awareness of this condition, which impacts over 82,000 people in the U.S. It’s our hope that You, Me and MG will provide a safe space for people to authentically connect with and learn from others living with MG. To learn more and join this community, visit us on Instagram: https://lnkd.in/e84GBHS8 #YouMeAndMG

Last week we co-hosted the “West Coast Summit: The Transformative Power of A.I. in Pharmaceutical R&D” with California Life Sciences (CLS).?? ? The day was packed with valuable insights from our expert panels who covered topics including the role A.I. plays in accelerating drug discovery, how A.I. can reduce drug development timelines, and what the investment landscape looks like for A.I. in pharmaceutical R&D.?? ? Congratulations to the Pitching A.I. for Pharmaceutical R&D QuickFire Challenge finalists:? ? - Ability Biologics | Lindsay Blore, M.B.A., Director Program Management? - Modicus Prime | Taylor Chartier, Ph.D., Chief Executive Officer, & David Vardanyan, Director of Engineering? - PrecisionLife | Rowan Gardner, Co-Founder & Chief Business & Investment Officer? - Synlico Inc. | Jingwei (Gavin) Lu, Ph.D., Founder & Chief Executive Officer? - ThinkingNode Life Science, Inc. | Jake Lesnik, Chief Business Officer? ? A special thank you to all that attended the program. To learn more about open QuickFire Challenges, visit - https://lnkd.in/etaadwxG?

There is one week left to register for the next installment of our Innovation Ignited webinar series taking place on October 16.?Attendees will gain insights into J&J's key priorities and future direction in precision medicine approaches in both oncology and immunology, uncovering potential collaborative opportunities between these fields.? ?? Join us to learn how founders, academics, and innovators can engage with us and ask questions directly to our expert panelists: ? ?? Carolyn Cuff, Ph.D., Vice President, Immunology Translational Science, Johnson & Johnson Innovative Medicine??? Ricardo Attar, Ph.D., Vice President, Oncology Translational Research, Johnson & Johnson Innovative Medicine?? Heike Keilhack, Ph.D., C.S.O., Rome Therapeutics?? ?? We hope you can attend!?RSVP now:?https://lnkd.in/e-SSm_zP

We are excited to present our groundbreaking data in gastroenterology at this week’s #UEGW2024. By leveraging our extensive knowledge and scientific expertise, we aim to provide transformative treatment options for patients worldwide living with inflammatory bowel diseases, ulcerative colitis (UC) or Crohn’s disease (CD). Discover more about our work here: https://lnkd.in/erjFets2 #JNJImmunology